As­traZeneca gets a $500M an­ti­body con­tract, yet key ques­tions still loom for Trump's new fa­vorite treat­ment

5 years ago
Coronavirus

The oust­ed spokesper­son that Stephen Hahn re­moved? FDA says she’s still an ap­pointee, but won’t say what she does

5 years ago
FDA+

Park­er In­sti­tute sum­moned the neoanti­gen pi­o­neers to com­pare their pre­dic­tion al­go­rithms. And they have some ...

5 years ago
Discovery

Brett Zbar to lead life sci­ences in­vest­ing at Gen­er­al At­lantic; Michael Ka­vanaugh plans re­tire­ment as Cy­tomX pro­motes ...

5 years ago
Peer Review

What are the right in­gre­di­ents for a block­buster uni­corn IPO? Nor­bert Bischof­berg­er has some thoughts on that

5 years ago
Financing
Bioregnum

Covid-19 roundup: Chi­na joins vac­cine dis­tri­b­u­tion pro­gram re­ject­ed by Trump; Take­da and CSL-led al­liance be­gins ...

5 years ago
Coronavirus

Pfiz­er's last bid to re­verse Lil­ly's CDK4/6 ear­ly-stage takeover fails, as a sec­ond Ibrance study fal­ters

5 years ago
R&D

Three more biotechs go pub­lic Fri­day as noth­ing seems able to slow down the 2020 train

5 years ago
Financing

As Trump touts his ‘great’ Covid drugs, the phar­ma cash flows to Biden, not him

5 years ago
Pharma

It's not just the an­ti­bod­ies: Eli Lil­ly bur­nish­es its sec­ond EUA in play with new Covid-19 da­ta on Olu­mi­ant plus ...

5 years ago
R&D
Coronavirus

In an­oth­er blow to In­ter­cept, the FDA is in­ves­ti­gat­ing Ocali­va for po­ten­tial risk of liv­er dis­or­der

5 years ago
FDA+

Seat­tle Ge­net­ics? Not any­more. The biotech has short­ened its name to Seagen to il­lus­trate glob­al ex­pan­sion

5 years ago
Pharma

Sen­sei Bio­ther­a­peu­tics rakes in $28.5M to give can­cer im­munother­a­pies a push

5 years ago
Financing

Am­gen's big car­dio­vas­cu­lar bet with Cy­to­ki­net­ics hits PhI­II pri­ma­ry but dra­mat­i­cal­ly dis­ap­points in­vestors

5 years ago
R&D

How hot is Hong Kong's biotech IPO mar­ket? Two biotechs just raised $800M to­tal

5 years ago
Financing
China

In an­oth­er PhI­II, Al­bert Bourla con­tin­ues to build case for a once-flopped GHD drug

5 years ago
R&D

As Mod­er­na dou­bles down on vac­cines, Mer­ck pulls out of a long-run­ning col­lab­o­ra­tion

5 years ago
R&D

Take­da drops $300M cash to kick off $1B RNAi al­liance with Ar­row­head, shoot­ing for first-in-class rare dis­ease drug

5 years ago
Deals

J&J, Cigna back a vant’s quest to go deep­er in­to the da­ta and start con­nect­ing the dots

5 years ago
Financing

FDA doc­u­ments raise opi­oid abuse po­ten­tial but pave a path to­ward bad­ly-need­ed ap­proval for Alk­er­mes

5 years ago
FDA+

Covid-19 roundup: Azar says US could have vac­cines for all by March; Mod­er­na gets $56M to build mo­bile vac­cine ...

5 years ago
Coronavirus

'I've au­tho­rized it' — Trump promis­es quick EUA and free ac­cess to Re­gen­eron's an­ti­body cock­tail, call­ing it a ...

5 years ago
Coronavirus

Not two weeks af­ter clos­ing a Se­ries D round, Galec­to files for $100M IPO

5 years ago
Financing

Af­ter two rounds of mixed da­ta, Eli Lil­ly im­press­es an­a­lysts with new Covid-19 an­ti­body re­sults. And ex­ecs want an ...

5 years ago
R&D
Coronavirus
First page Previous page 792793794795796797798 Next page Last page
A service from the Financial Times